Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Autolus is confident in its supply chain after it was already been tested under “the most difficult circumstances” during its FELIX study over the peak of the COVID-19 pandemic. Currently, the product ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

“Our COVID-19 projections are largely unchanged ... to proceed with its $27.8 billion acquisition of Horizon Therapeutics ...

In announcing RFK Jr. as having a significant role in healthcare in his administration, he has targeted healthcare in America ...

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) on November 6 and set a ...

Some recovery was aided by the contribution of COVID-19 drugs. While the company retired a fifth of ... while Gilead ...

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...